When President Donald Trump decides to change the situation, he does not tiptoe. This year, Trump has been on a mission to boost US energy production, with his eyes now firmly set on nuclear power. Most recently, that mission took shape in the form of an $80 billion deal with nuclear powerhouse Westinghouse, aimed at building a new fleet of nuclear reactors across the United States.
The deal, announced on October 28, brings together Canadian uranium producer Cameco (CCJ) and investment giant Brookfield Asset Management (BAM) in a strategic partnership. The move directly responds to Trump’s executive orders from May, which set a goal of quadrupling US nuclear capacity by 2050.
Somewhere in this powerful story are ASP isotopes (ASPI), emerging as beneficiaries of the nuclear wave. For an investor who likes both science and momentum, this name suddenly seems like a headline. ASPI shares rose 3.4% intraday after the news on October 28.
ASPI stock also saw a 31% intraday rise on October 13 after the company revealed recent trading updates. In fact, ASP Isotopes reported that it had closed important supply agreements, expanded production and moved into the radiopharmaceuticals sector. That sequence turned a political push into business realities and caused investors to reevaluate what growth could look like when government strategy meets private capacity.
These upgrades caused the stock to hit a new 52-week high of $14.49 on October 14. That said, it appears to be the beginning of a completely new era in energy innovation for ASP isotopes.
ASP Isotopes (ASPI), headquartered in Washington, DC, is an advanced materials company specializing in isotope enrichment technologies that power everything from nuclear medicine and clean energy to advanced industrial applications. With a market capitalization of nearly $841 million, its products help drive medical imaging systems, advances in drug development, and next-generation nuclear reactors.
Year to date (YTD), ASPI stock is up 94%. The rebound has only intensified, with a jump of 37% in the last six months.
www.barchart.com
Currently, ASPI is valued at 172 times sales, which is a staggering figure compared to the industry average. However, these figures are not solely the result of exaggerations. They also show conviction.
Aug. 15 brought a mix of progress and pressure for ASP Isotopes when it reported second-quarter fiscal 2025 results. The company posted revenue of $1.2 million, up 17% year-over-year, thanks in large part to strong sales of nuclear medical doses from PET Labs. Still, it fell short of Wall Street’s $1.6 million forecast.
The slight failure did not overshadow the story of steady progress. Gross profit increased 36% year over year (YOY) to $572,100, showing that the company’s fundamentals are intact despite some growing pains.
Operationally, ASP Isotopes continues to move towards full commercial operations. But expansion comes at a price. Operating expenses increased 59% year over year to $12.5 million, driven by an 86% increase in R&D spending to $879,900 and a 57% increase in selling, general and administrative costs to $11.7 million.
The bottom line showed a net loss of $75.2 million, a huge deterioration from last year’s figure, mainly due to a non-cash charge of $63.8 million linked to changes in the fair value of the convertible notes. Meanwhile, loss per share rose 329% from the prior-year quarter to $1.03 and missed analyst expectations of $0.11.
Still, liquidity remains strong, with $67.7 million in cash and equivalents at the end of June, supported by newly raised capital. Additionally, management remains confident, as three isotope enrichment plants are now operational and the company has completed its first customer shipments of ytterbium-176 and silicon-28.
ASP Isotopes projects that revenue from new isotopes will reach between $50 million and $70 million in 2026, paving the way for strong leadership in the industry. Meanwhile, analysts expect third-quarter fiscal 2025 EPS to rise a staggering 832,600%.
Wall Street’s outlook for ASPI stock is optimistic. The stock has a “Strong Buy” consensus, and one analyst rated it a “Strong Buy.” The $11 average price target indicates 21% upside potential from current levels.
Among the voices applauding ASPI the loudest is Lucid Capital analyst Alex Fuhrman, with a “Buy” rating and a $15 price target. The analyst believes ASP Isotopes is “entering a rapid growth phase,” driven by its transition to commercial isotope production.
www.barchart.com
On the date of publication, Aanchal Sugandh had no (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com
